Healthcare / BiotechnologyNasdaqCM
$1.28
-0.04 (-3.03%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-4.1M · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
12/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-57.8%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2008–2025 · 17 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-3.1M · FCF $-2.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||||
| Revenue | — | — | — | — | — | — | $1.07B | $1.07B | $1.07B | $1.07B | — | — | — | — | — | — | — | — | — |
| Net Income | $-3.1M | $-3.1M | $-4.1M | $-8.9M | $-1.5M | $-1.6M | $-1.8M | $-3.4M | $-4.4M | $-7.1M | $-25.9M | $-13.9M | $-4.4M | $-1.1M | $-5631.00 | $-4920.00 | $-3597.00 | $-10285.00 | $-13343.00 |
| EBITDA | $-3.2M | $-3.2M | $-4.2M | $-9.4M | $-3.7M | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -2.65 | -2.65 | -28.96 | -204.06 | -186.90 | -504.00 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | -0.1% | -0.2% | -0.3% | -0.2% | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | -0.2% | -0.3% | -0.4% | -0.7% | — | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||||
| Current Ratio | 13.85 | 13.85 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||||
| Free Cash Flow | $-2.7M | $-2.7M | $-4.1M | $-9.6M | $-3.6M | — | — | — | — | — | — | $-3.5M | $-2.8M | — | — | — | — | — | — |
| Returns | |||||||||||||||||||
| ROE | -57.8% | -57.8% | -118.0% | -307.9% | -25.0% | -24.5% | 13.3% | 28.9% | 51.5% | 84.0% | 309.4% | 330.6% | 119.6% | 19.3% | 16.3% | 17.0% | 15.0% | 50.3% | 131.3% |
| Valuation | |||||||||||||||||||
| P/B | 0.28 | 0.28 | 0.48 | 0.47 | 0.47 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | 90.8% | 90.8% | 85.8% | -9.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-75.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-28.96 → -2.65
Residual
-75.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.